Navigation Links
Helix BioPharma to Present at the BioFinance 2009 Conference
Date:4/24/2009

by the use of forward-looking terminology such as "will", "developing", "April 29", or comparable terminology referring to future events or results. Forward looking statements are statements about the future and are inherently uncertain, and Helix's actual results could differ materially from those anticipated in these forward-looking statements as a result of numerous factors, including without limitation, the risk that the BioFinance presentation and the posting of the slide show portion of the presentation are subject to change or cancellation without notice; uncertainty whether L-DOS47 or Topical Interferon Alpha-2b will be successfully developed as a drug or otherwise commercialized; the need for additional research and development, the outcome of which is uncertain; the need for clinical trials, the occurrence and success of which cannot be assured; product liability and insurance risks; the risk of technical obsolescence; the need for regulatory approvals, which may not be obtained in a timely matter or at all; intellectual property risks; marketing/manufacturing and partnership/strategic alliance risks; the effect of competition; Helix's need for additional future capital, which may not be available in a timely manner or at all; as well as a description of other risks and uncertainties affecting Helix and its business, as contained in news releases and filings with the Canadian Securities Regulatory Authorities, any of which could cause actual results to vary materially from current results or Helix's anticipated future results. Forward-looking statements are based on the beliefs, assumptions, opinions and expectations of Helix's management at the time they are made, and Helix does not assume any obligation, except as required by law, to update any forward-looking statement should those beliefs, assumptions or expectations, or other circumstances change.


'/>"/>
SOURCE Helix BioPharma Corp.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. Helix Biopharma announces addition of University of Arizona professor Kenneth Hatch as new medical advisor
2. Helix BioPharma Chairman resigns
3. Helix BioPharma Corp. announces fiscal 2007 results
4. Helix BioPharma Corp. announces management changes
5. Helix BioPharma announces $16.9 million private placement of common shares
6. Helix BioPharma announces Q1 2008 financial results
7. Helix BioPharma closes $16.9 million private placement of common shares
8. Helix BioPharma Corp. contracts KBI Biopharma to develop an L-DOS47 clinical packaging format
9. Helix BioPharma shareholders vote in favour of management
10. Helix BioPharma reports Q2 2008 highlights, financial results
11. W. Thomas Hodgson appointed to board of Helix BioPharma Corp.
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/22/2014)... Dec. 22, 2014  ( www.competitivehealth.com ) — Competitive ... medical bill review and advocacy service, has signed an ... WellCard Savings discount health services marketplace. 63% ... more than they expected to pay. As part of ... costs, WellCard Savings is pleased to offer medical bill ...
(Date:12/22/2014)... 22, 2014 Fertility Associates of Memphis ... Bank USA , a network of more than 20 ... partnership, patients have fast access to a national pool ... IVF . Fertility Associates of Memphis is the only ... treatment option. , Dr. William Kutteh , director ...
(Date:12/19/2014)... BioPlus Specialty Pharmacy (BioPlus), one ... of Nick Maroulis, Pharm.D. to the newly created position ... In this position, Dr. Maroulis will continue to manage ... of our multi-site pharmacies as the company expands. Dr. ... that time he has served in many different capacities ...
(Date:12/19/2014)... Dec. 19, 2014 Bina Technologies, Inc. (Bina, ... that they have been acquired by Roche (SIX: RO, ... privately held company that provides a big data platform ... (NGS) data for the academic and translational research markets. ... and will continue to focus on development of their ...
Breaking Biology Technology:WellCard Savings Announces CoPatient Medical Bill Review Service for Members 2Fertility Associates of Memphis Announces Partnership with Donor Egg Bank USA 2Fertility Associates of Memphis Announces Partnership with Donor Egg Bank USA 3BioPlus Specialty Pharmacy Promotes Dr. Nick Maroulis to Vice President of Specialty Pharmacy Services 2Bina Technologies is acquired by Roche. 2Bina Technologies is acquired by Roche. 3
... , , , , Multiporator / Electroporator 2510 , , , ... Transformation Protocol , Protocol No. 4308 915.524 03/2002 , ... , , , , ... , Cell type , Bacteria, ...
... , , , Multiporator / Electroporator 2510 , , , , ... Transformation Protocol , Protocol No. 4308 915.519 12/2001 , ... , , , ... , Cell type , Bacteria, gram positive, ...
... , , , Multiporator / Electroporator 2510 , , , , , ... Transformation Protocol , Protocol No. 4308 915.520 12/2001 , ... , , , Microorganism , ... Cell type , Bacteria, gram positive, ...
Cached Biology Technology:Mycobacterium tuberculosis 2Lactococcus lactis 2Listeria monocytogenes 2
(Date:12/22/2014)... 2014 Research and Markets ... of the "The Global Watermarking and ... http://photos.prnewswire.com/prnh/20130307/600769 ... of the global digital media watermarking and ... monitor piracy by securely and invisibly embedding ...
(Date:12/19/2014)... 2014  23andMe, Inc., the leading personal genetics company, ... fine-scale differences in genetic ancestry of individuals from across ... Since immigrants first arrived more than four hundred years ... served as a meeting place for peoples from different ... ongoing mixing of peoples with African, European, and American ...
(Date:12/17/2014)... 15, 2014  HITLAB SM announced today ... audit to confirm its adherence to current U.S. ... enables HITLAB to conduct regulated smart device and ... for patient safety and research quality. ... quality, and delivery with innovative technology," said ...
Breaking Biology News(10 mins):The Global Watermarking and Fingerprinting Markets 223andMe Study Sketches Genetic Portrait of the United States 223andMe Study Sketches Genetic Portrait of the United States 323andMe Study Sketches Genetic Portrait of the United States 4HITLAB Completes GCP Audit for FDA Smart Device & App Compliance 2
... called microRNAs, control protein production primarily by causing the ... to be disabled by the cell, according to Whitehead ... microRNAs control protein production by causing the mRNAs to ... microRNAs impart by jamming the process that translates mRNAs ...
... Aug. 16, 2010 A very aggressive disease with ... higher exposure to estrogens, according to a group of ... Dr. Jan-ke Gustafsson, Robert A. Welch Professor in UH,s ... a paper titled "Estrogen-dependent gallbladder carcinogenesis in LXRβ-/- female ...
... WI, August 16th, 2010 - Fields amended with ... according to studies by USDA-Agricultural Research Service (ARS) ... about the agricultural pollutants that can build up ... nearby streams and rivers. Poultry producers ...
Cached Biology News:RNA snippets control protein production by disabling mRNAs 2RNA snippets control protein production by disabling mRNAs 3Gallbladder cancer may be linked to estrogens, says UH team 2Arsenic in field runoff linked to poultry litter 2
Request Info...
...
... potent inhibition of RNase A-type ribonucleases Product ... of nonhuman origin that binds noncovalently and ... A, B, and C). It does not ... U2, or CL3. QIAGEN RNase Inhibitor inhibits ...
Request Info...
Biology Products: